AU2002256095A1 - Method for the treatment of polycystic kidney disease - Google Patents

Method for the treatment of polycystic kidney disease

Info

Publication number
AU2002256095A1
AU2002256095A1 AU2002256095A AU2002256095A AU2002256095A1 AU 2002256095 A1 AU2002256095 A1 AU 2002256095A1 AU 2002256095 A AU2002256095 A AU 2002256095A AU 2002256095 A AU2002256095 A AU 2002256095A AU 2002256095 A1 AU2002256095 A1 AU 2002256095A1
Authority
AU
Australia
Prior art keywords
treatment
kidney disease
polycystic kidney
polycystic
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002256095A
Inventor
Philip Frost
Jeremy Ian Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of AU2002256095A1 publication Critical patent/AU2002256095A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002256095A 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease Abandoned AU2002256095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28308701P 2001-04-11 2001-04-11
US60/283,087 2001-04-11
PCT/US2002/010751 WO2002083112A2 (en) 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
AU2002256095A1 true AU2002256095A1 (en) 2002-10-28

Family

ID=23084450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256095A Abandoned AU2002256095A1 (en) 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease

Country Status (4)

Country Link
AU (1) AU2002256095A1 (en)
BR (1) BR0208784A (en)
CA (1) CA2357110A1 (en)
WO (1) WO2002083112A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485346C (en) 2002-06-12 2013-05-28 Exelixis, Inc. Human adam-10 inhibitors
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GT200500139A (en) * 2004-06-08 2005-07-25 METHOD FOR THE PREPARATION OF HYDROXAMIC ACIDS
EP1781318A4 (en) * 2004-06-23 2009-12-23 Genzyme Corp Methods and compositions for the treatment of polycystic diseases
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AR035313A1 (en) * 1999-01-27 2004-05-12 Wyeth Corp ACETILENIC TACE INHIBITORS OF HYDROXAMIC ACID OF SULFONAMIDE BASED ON ALFA-AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES.
DK1144369T3 (en) * 1999-01-27 2004-11-01 Wyeth Corp Acetylenic arylsulfonamide and phosphinic acid amide hydroxamic acid derivatives as TACE inhibitors
AR022423A1 (en) * 1999-01-27 2002-09-04 American Cyanamid Co COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2357110A1 (en) 2002-10-11
WO2002083112A3 (en) 2003-09-25
WO2002083112A2 (en) 2002-10-24
BR0208784A (en) 2004-06-22

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
AU2002257936A1 (en) Methods of well treatment
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2001285747A1 (en) Method for the treatment of tobacco
AU2002310034A1 (en) Process for the preparation of 3-hydroxypropanal
AU2002256095A1 (en) Method for the treatment of polycystic kidney disease
AU2763101A (en) Screening methods for compounds useful in the treatment of polycystic kidney disease
AU2002329441A1 (en) Process for the preparation of 3 - isochromanone
MXPA03006923A (en) Method for alteration of iris pigment.
AUPR963401A0 (en) Methods for the enhancement of complex peaks
AUPR731901A0 (en) Method of treatment
AU2002358085A1 (en) Process for the preparation of 4-methyl-7-aminoquinolones
AU2002302604A1 (en) Process connection
AU2002324291A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2002250044A1 (en) Method for the treatment of peripheral vascular disease
AU2002313461A1 (en) Method for the hydrophobic treatment of wood
AUPR950401A0 (en) Methods for treatment
AUPR634001A0 (en) Method of treatment
AUPR542201A0 (en) Method of treatment
AU2002307061A1 (en) Method of treatment
AUPR750701A0 (en) Method of treatment
AU2002237631A1 (en) Method of treatment
AUPR579801A0 (en) Method of treatment
AU2002257938A1 (en) Method of treatment
AU2002257731A1 (en) Method of well treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase